Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

被引：0

作者：

Chatzikonstantinou, Thomas ^{[1
]}

Scarfo, Lydia ^{[2
,3
]}

Minga, Eva ^{[1
]}

Karakatsoulis, Georgios ^{[1
]}

Chamou, Dimitra ^{[1
]}

Kotaskova, Jana ^{[4
,5
,6
]}

Iacoboni, Gloria ^{[7
]}

Demosthenous, Christos ^{[8
,9
]}

Albi, Elisa ^{[2
]}

Alcoceba, Miguel ^{[10
,11
]}

Al-Shemari, Salem ^{[12
]}

Aurran-Schleinitz, Therese ^{[13
]}

Bacchiarri, Francesca ^{[14
]}

Chatzileontiadou, Sofia ^{[15
]}

Collado, Rosa ^{[16
]}

Davis, Zadie ^{[17
]}

de Deus Santos, Marcos Daniel ^{[18
]}

Dimou, Maria ^{[19
]}

Dmitrieva, Elena ^{[20
]}

Donaldson, David ^{[21
]}

Dos Santos, Gimena ^{[22
]}

Dreta, Barbara ^{[23
]}

Efstathopoulou, Maria ^{[24
]}

El-Ashwah, Shaimaa ^{[25
]}

Enrico, Alicia ^{[26
]}

Frygier, Andrzej ^{[27
]}

Galimberti, Sara ^{[28
]}

Galitzia, Andrea ^{[29
]}

Gimeno, Eva ^{[30
]}

Guarente, Valerio ^{[31
,32
,33
]}

Guieze, Romain ^{[34
]}

Harrop, Sean ^{[35
]}

Hatzimichael, Eleftheria ^{[36
]}

Herishanu, Yair ^{[37
,38
]}

Hernandez-Rivas, Jose-angel ^{[39
]}

Jaksic, Ozren ^{[40
]}

Kalicinska, Elzbieta ^{[41
]}

Laribi, Kamel ^{[42
]}

Karakus, Volkan ^{[43
]}

Kater, Arnon P. ^{[44
]}

Kho, Bonnie ^{[45
]}

Kislova, Maria ^{[20
]}

Konstantinou, Eliana ^{[46
]}

Koren-Michowitz, Maya ^{[47
,48
]}

Kotsianidis, Ioannis ^{[49
]}

Kubova, Zuzana ^{[50
,51
]}

Labrador, Jorge ^{[52
]}

Lad, Deepesh ^{[53
]}

Laurenti, Luca ^{[54
,55
]}

Longval, Thomas ^{[56
]}

机构：

[1] Ctr Res & Technol Hellas, Inst Appl Biosci, Thessaloniki, Greece

[2] Univ Vita Salute San Raffaele, Milan, Italy

[3] IRCCS Osped San Raffaele, Milan, Italy

[4] Masaryk Univ, Cent European Inst Technol CEITEC, Brno, Czech Republic

[5] Masaryk Univ, Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[6] Masaryk Univ, Fac Med, Brno, Czech Republic

[7] Univ Hosp Vall dHebron, Dept Hematol, Barcelona, Spain

[8] G Papanicolaou Hosp, Hematol Dept, Thessaloniki, Greece

[9] G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece

[10] Univ Hosp Salamanca HUS IBSAL, Dept Haematol, CIBERONC CB16 12 00233, Salamanca, Spain

[11] Canc Res Ctr CIC IBMCC USAL CSIC, Salamanca, Spain

[12] Kuwait Univ, Fac Med, Dept Med, Kuwait, Kuwait

[13] Inst Paoli Calmettes, Dept Hematooncol, Marseille, France

[14] Univ Siena, Div Hematol, Siena, Italy

[15] AUTH, AHEPA Hosp, Dept Internal Med 1, Hematol Unit, Thessaloniki, Greece

[16] Fdn Invest Hosp Gen Univ Valencia, Consorcio Hosp Gen Univ Valencia, Serv Hematol, Valencia, Spain

[17] Royal Bournemouth Hosp, Dept Haematol, Bournemouth, Dorset, England

[18] Univ Fed Espirito St, Internal Med Dept, Vila Velha, ES, Brazil

[19] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Hematol & Bone Marrow Transplantat, Athens, Greece

[20] SP Botkins City Hosp, Dept Hematol Oncol & Chemotherapy, Moscow, Russia

[21] Belfast City Hosp, Clin Haematol, Belfast, North Ireland

[22] Hosp Clin Montevideo, Montevideo, Uruguay

[23] Univ Hosp Ctr Zagreb, Dept Internal Med, Div Hematol, Zagreb, Croatia

[24] Athens Med Ctr Psychikon Branch, Dept Haematol, Athens, Greece

[25] Mansoura Univ, Oncol Ctr, Mansoura, Egypt

[26] Hosp Italiano La Plata, La Plata, Buenos Aires, Argentina

[27] Hull York Med Sch, Kingston Upon Hull, England

[28] Univ Pisa, Dept Clin & Expt Med, Sect Hematol, Pisa, Italy

[29] Osped Oncol A Businco, ARNAS G Brotzu, Hematol & Stem Cell Transplantat Unit, Cagliari, Italy

[30] Hosp Mar, Dept Hematol, Barcelona, Spain

[31] Univ Perugia, Inst Hematol, Perugia, Italy

[32] Univ Perugia, Ctr Hematooncol Res, Perugia, Italy

[33] Santa Maria Misericordia Hosp, Perugia, Italy

[34] Estaing Univ Hosp, Dept Hematol & Cell Therapy, Clermont Ferrand, France

[35] Univ Melbourne, St Vincents Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[36] Univ Ioannina, Fac Med, Sch Hlth Sci, Dept Haematol, Ioannina, Greece

[37] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Hematol, Tel Aviv, Israel

[38] Tel Aviv Univ, Fac Med, Tel Aviv, Israel

[39] Infanta Leonor Univ Hosp, Pathol Dept, Madrid, Spain

[40] Univ Hosp Dubrava, Dept Hematol, Zagreb, Croatia

[41] Wroclaw Med Univ, Dept & Clin Hematol Blood Neoplasms & Bone Marrow, Wroclaw, Poland

[42] Ctr Hosp Le Mans, Dept Hematol, Le Mans, France

[43] Antalya Training & Res Hosp, Antalya, Turkiye

[44] Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Hematol, Amsterdam, Netherlands

[45] Pamela Youde Nethersole Eastern Hosp, Dept Med, Chai Wan, Hong Kong, Peoples R China

[46] Univ Athens, Laikon Gen Hosp, Dept Haematol, Athens, Greece

[47] Shamir Med Ctr, Dept Hematol, Zerifin, Israel

[48] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[49] Democritus Univ Thrace, Univ Hosp Alexandroupolis, Dept Hematol, Alexandroupolis, Greece

[50] Palacky Univ, Fac Med & Dent, Dept Hematooncol, Olomouc, Czech Republic

来源：

HEMASPHERE | 2024年 / 8卷 / 09期

关键词：

VENETOCLAX; RITUXIMAB;

D O I：

10.1002/hem3.70004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：7

共 50 条

[41] Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study
Mauro, Francesca Romana
Paoloni, Francesca
Molica, Stefano
Reda, Gianluigi
Trentin, Livio
Sportoletti, Paolo
Marchetti, Monia
Pietrasanta, Daniela
Marasca, Roberto
Gaidano, Gianluca
Coscia, Marta
Stelitano, Caterina
Mannina, Donato
Di Renzo, Nicola
Ilariucci, Fiorella
Liberati, Anna Marina
Orsucci, Lorella
Re, Francesca
Tani, Monica
Musuraca, Gerardo
Gottardi, Daniela
Zinzani, Pier Luigi
Gozzetti, Alessandro
Molinari, Annalia
Gentile, Massimo
Chiarenza, Annalisa
Laurenti, Luca
Varettoni, Marzia
Ibatici, Adalberto
Murru, Roberta
Ruocco, Valeria
Del Giudice, Ilaria
De Propris, Maria Stefania
Della Starza, Irene
Raponi, Sara
Nanni, Mauro
Fazi, Paola
Neri, Antonino
Guarini, Anna
Rigolin, Gian Matteo
Piciocchi, Alfonso
Cuneo, Antonio
Foa, Robin
CANCERS, 2022, 14 (01)
[42] Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study
Ghosh, Nilanjan
Eyre, Toby A.
Brown, Jennifer R.
Lamanna, Nicole
Manzoor, Beenish S.
Coombs, Catherine C.
Tuncer, Hande H.
Ujjani, Chaitra
Leslie, Lori A.
Roeker, Lindsey E.
Davids, Matthew S.
Rhodes, Joanna M.
Skarbnik, Alan P.
Sinai, Wendy
Fleury, Isabelle
Hill, Brian T.
Martinez-Calle, Nicolas
Barr, Paul M.
Jawaid, Dureshahwar
Emechebe, Nnadozie
Pearson, Laurie
Lansigan, Frederick
Choi, Yun
Jensen, Christopher E.
Fakhri, Bita
Stephens, Deborah M.
Marx, Steven E.
Schuster, Stephen J.
Coyle, Michael
Pivneva, Irina
Watson, Talissa
Guerin, Annie
Shadman, Mazyar
AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (03) : 511 - 515
[43] Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study
Autore, Francesco
Visentin, Andrea
Deodato, Marina
Vitale, Candida
Galli, Eugenio
Fresa, Alberto
Fazzi, Rita
Sanna, Alessandro
Olivieri, Jacopo
Scortechini, Ilaria
Del Principe, Maria Ilaria
Sportoletti, Paolo
Schiattone, Luana
Maschio, Nilla
Facchinelli, Davide
Marchesi, Francesco
Coscia, Marta
Tedeschi, Alessandra
Trentin, Livio
Innocenti, Idanna
Candoni, Anna
Busca, Alessandro
Pagano, Livio
Laurenti, Luca
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (05) : 982 - 984
[44] Safety and Efficacy of Bendamustine Monotherapy in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: Polish Lymphoma Research Group Real-Life Analysis
Wolowiec, Dariusz
Szymczyk, Agnieszka
Potoczek, Stanislaw
Krochmalczyk, Dorota
Zawirska, Daria
Piotrowska, Magdalena
Malenda, Agata
Soroka-Wojtaszko, Maria
Kopacz, Agnieszka
Wasik-Szczepanek, Ewa
Grabos-Michalak, Jolanta
Razny, Malgorzata
Wichary, Ryszard
Bramowicz-Jarosz, Bozena
Seweryn, Marek
Dlugosz-Danecka, Monika
Hus, Iwona
CHEMOTHERAPY, 2019, 64 (03) : 155 - 162
[45] The European Medicines Agency Review of Ofatumumab (Arzerra®) for the Treatment of Chronic Lymphocytic Leukemia in Patients Refractory to Fludarabine and Alemtuzumab: Summary of the Scientific Assessment of the European Medicines Agency Committee for Medicinal Products for Human Use
Gravanis, Iordanis
Ersboll, Jens
Skovlund, Eva
Abadie, Eric
Marty, Michel
Pignatti, Francesco
ONCOLOGIST, 2010, 15 (12) : 1335 - 1343
[46] Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial
Pettitt, Andrew R.
Jackson, Richard
Carruthers, Stacey
Dodd, James
Dodd, Susanna
Oates, Melanie
Johnson, Gillian G.
Schuh, Anna
Matutes, Estella
Dearden, Claire E.
Catovsky, Daniel
Radford, John A.
Bloor, Adrian
Follows, George A.
Devereux, Stephen
Kruger, Anton
Blundell, Julie
Agrawal, Samir
Allsup, David
Proctor, Stephen
Heartin, Earnest
Oscier, David
Hamblin, Terry J.
Rawstron, Andrew
Hillmen, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) : 1647 - 1655
[47] Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group
Smolej, Lukas
Brychtova, Yvona
Cmunt, Eduard
Doubek, Michael
Spacek, Martin
Belada, David
Simkovic, Martin
Stejskal, Lukas
Zygulova, Irena
Urbanova, Renata
Brejcha, Martin
Zuchnicka, Jana
Mocikova, Heidi
Kozak, Tomas
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (04) : 769 - 778
[48] Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia
van der Straten, Lina
Kater, Arnon P.
Doorduijn, Jeanette K.
van den Broek, Esther C.
Posthuma, Eduardus F. M.
Dinmohamed, Avinash G.
Levin, Mark-David
ANNALS OF HEMATOLOGY, 2020, 99 (05) : 1081 - 1091
[49] 6-Year Time to Next Treatment (TTNT) Extrapolation Curve for GLOW Study: First-Line Ibrutinib Plus Venetoclax (I plus V) Offers Long Treatment-Free Period for Older Adult/Unfit Patients With Chronic Lymphocytic Leukemia (CLL)
Ossorio Prendes, Santiago
Gimeno, Vicente
Hernandez Rivas, Jose Angel
Lopez Jimenez, Francisco Javier
Diels, Joris
Schioppa, Claudio
Alfayate Lobo, Ana
Dominguez-Lubillo, Teresa
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S355 - S356
[50] Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience
Herishanu, Yair
Tadmor, Tamar
Braester, Andrei
Bairey, Osnat
Aviv, Ariel
Rahimi-Levene, Naomi
Fineman, Riva
Levi, Itai
Yuklea, Mona
Ruchlemer, Rosa
Shvidel, Lev
Polliack, Aaron
HEMATOLOGICAL ONCOLOGY, 2019, 37 (02) : 185 - 192

← 1 2 3 4 5 →